[Asia Economy Reporter Jang Hyowon] Dragonfly is showing strong performance. This is interpreted as being influenced by the news that the domestic pharmaceutical industry is also experiencing a wave of therapeutic development amid active research and development of digital therapeutics overseas.
As of 9:14 AM on the 18th, Dragonfly is trading at 854 won, up 7.68% compared to the previous day.
Digital therapeutics refer to software that treats diseases. The Ministry of Food and Drug Safety classifies them as digital medical devices. Generally, games, applications, and virtual reality (VR) are utilized, and they are called the third-generation therapeutics following first-generation synthetic drugs and second-generation biopharmaceuticals.
According to the industry, more than 20 digital therapeutics have been approved by the U.S. Food and Drug Administration (FDA) overseas. In 2020, the first game-type digital therapeutic, ‘Endeavor,’ was approved. This game was approved as a treatment for ADHD in children aged 8 to 12. It is a therapeutic that can improve concentration through gameplay.
The digital therapeutics market is also growing. According to the National Biotechnology Policy Research Center, the digital therapeutics market size, which was about 5.1895 trillion won last year, is expected to grow at an average annual rate of 20.5% and reach 23 trillion won by 2030. The government is also actively promoting the introduction of digital therapeutics.
Dragonfly is a game company that owns the intellectual property (IP) of the first-person shooter (FPS) game Special Force, and has developed the ADHD digital therapeutic ‘Guardians DTx’ by leveraging its expertise. In November last year, it submitted a clinical trial plan to the Ministry of Food and Drug Safety for application to children aged 7 to 13 with ADHD.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
